Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia

Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia

©2020 American Association for Cancer Research. PURPOSE: Children with Down syndrome (constitutive trisomy 21) that develop acute lymphoblastic leukemia (DS-ALL) have a 3-fold increased likelihood of treatment-related mortality coupled with a higher cumulative incidence of relapse, compared with oth...

Full description

Bibliographic Details
Main Authors: Laurent, A.P., Siret, A., Ignacimouttou, C., Panchal, K., Diop, M., Jenni, S., Tsai, Y.C., Roos-Weil, D., Aid, Z., Prade, N., Lagarde, S., Plassard, D., Pierron, G., Daudigeos, E., Lecluse, Y., Droin, N., Bornhauser, B.C., Cheung, Laurence, Crispino, J.D., Gaudry, M., Bernard, O.A., Macintyre, E., Barin Bonnigal, C., Kotecha, Rishi, Geoerger, B., Ballerini, P., Bourquin, J.P., Delabesse, E., Mercher, T., Malinge, S.
Format: Journal Article
Language:English
Published: AMER ASSOC CANCER RESEARCH 2020
Subjects:
Science & Technology
Life Sciences & Biomedicine
Oncology
ACUTE LYMPHOBLASTIC-LEUKEMIA
GENOMIC LANDSCAPE
CRITICAL REGION
RAS PATHWAY
JAK2
CHROMOSOME-21
EXPRESSION
MUTATIONS
CANCER
CRLF2
Online Access:http://purl.org/au-research/grants/nhmrc/1142627
http://hdl.handle.net/20.500.11937/81080

Similar Items

Similar Items